{"entity":{"id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Adebrelimab and Gemcitabine in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07229586 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 100 participants planned, started 2025-12-02 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-7367 Injection, SHR-1316 Injection, Paclitaxel for Injection and Gemcitabine Hydrochloride for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07229586","url":"https://clinicaltrials.gov/study/NCT07229586"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["adebrelimab","gemcitabine"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07229586","phase":"1/2","setting":"A Phase IB/II Clinical Study of the Safety, Tolerability and Efficacy of SHR-7367 in Combination With Anti-tumor Agents in Subjects With Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct07229586/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}